MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-101430-PIP01-24) and to the deferral.

MHRA-101430-PIP01-24-M01

Scope of the Application

Active Substance(s)

RAVULIZUMAB

Condition(s)

Treatment in haematopoietic stem cell transplantation

Pharmaceutical Form(s)

Concentrate for solution for infusion; Solution for injection

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Alexion Europe SAS

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Alexion Europe SAS submitted to the licensing authority on 08/04/2025 19:10 BST an application for a Modification

The procedure started on 19/08/2025 18:17 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101430-PIP01-24-M01

Of 26/08/2025 14:53 BST

On the adopted decision for RAVULIZUMAB (MHRA-101430-PIP01-24-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for RAVULIZUMAB, Concentrate for solution for infusion; Solution for injection , INTRAVENOUS USE .

This decision is addressed to Alexion Europe SAS, 103-105 rue Anatole , Levallois-Perret , FRANCE, 92300

ANNEX I

1. Waiver

1.1 Condition:

Treatment in haematopoietic stem cell transplantation. The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 28 days of age. Pharmaceutical form(s): Concentrate for solution for infusion Solution for injection Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment in haematopoietic stem cell transplantation.

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients with haematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA).

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 28 days to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Concentrate for solution for infusion Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 1 (ALXN1210-TMA-314) Open-label, single-arm trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of ravulizumab as add-on to best supportive care (BSC) in paediatric patients from 28 days to less than 18 years of age with thrombotic microangiopathy (TMA) after haematopoietic stem cell transplantation (HSCT). Study 2 (ALXN1210-TMA-313) Double-blind, randomised, placebo-controlled trial to evaluate efficacy and safety of ravulizumab in adolescents from 12 years to less than 18 years of age (and adults) with thrombotic microangiopathy (TMA) after haematopoietic stem cell transplantation (HSCT).
Extrapolation, Modeling & Simulation Studies	1	Study 3 Extrapolation study to support extrapolation of efficacy, pharmacokinetics/ pharmacodynamics, and safety of ravulizumab in patients with HSCT-TMA from 28 days to less than 18 years of age. (Added during

		procedure MHRA-101430-PIP01-24-M01.)
Other Studies	0	Not applicable.
Other Measures	1	Extrapolation plan Studies 1, 2 and 3 are part of the extrapolation plan of pharmacokinetics/ pharmacodynamics, safety and efficacy data covering the paediatric population from 28 days to less than 18 years of age with HSCT-TMA. (Added during procedure MHRA-101430-PIP01-24-M01.)

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2026
Deferral of one or more studies contained in the paediatric investigation plan:	No